DMII DMII
Company Profile ↓Company Overview
DMII (DMII) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +2.33% |
| 6 Months: | +1.40% |
| 3 Months: | +0.95% |
| 1 Month: | +0.20% |
- Price vs 50-DMAAbove
- RSI (14)58.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Income | -59.33K | - | -155.51K | -132.03K |
| Net Income | -59.33K | -38.07K | -46.16K | 4.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Income | -488.38K |
| Net Income | 4.19M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 138.06K | 504.96M |
| Total Equity | -116.72K | -17.77M |
| Cash & Equivalents | - | 223 |
| Total Liabilities | 254.78K | 17.80M |
| Current Liabilities | 254.78K | 300.86K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Cash Flow | -1.02M |
| Investing Cash Flow | -500.00M |
| Financing Cash Flow | 501.00M |
| Capital Expenditure | - |
| Free Cash Flow | -1.02M |
| Net Change in Cash | -16.81K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2025 |
|---|---|
| Gross Margin % | - |
| Operating Margin % | - |
| Net Margin % | - |
| ROE % | -23.6% |
| ROCE % | -0.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DMII
NexGen Energy’s Rook I Project Emerges as a Key Source in the Next Uranium Supply Wave
MMCAP International increased its stake in NexGen Energy during the fourth quarter, deepening exposure to the company’s Rook I uranium project in Canada. As governments extend reactor lifespans and reconsider nuclear expansion, attention is…
Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company
Key Insights Institutions' substantial holdings in Drugs Made In America Acquisition II implies that they have...
DMII — Frequently Asked Questions
What is the current share price of DMII?
As of 2026-08-05 17:25 PDT, DMII trades at $10.11 on NASDAQ/NYSE. Its 52-week range is $9.87 to $10.12.
What is the return on equity (ROE) of DMII?
DMII has a return on equity (ROE) of -23.56%. Its return on capital employed (ROCE) is -0.10%.
Is DMII a good stock to buy?
This page provides a data-driven analysis of DMII, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.